AstraZeneca stock pre-market at EUR 142.18: minus 0.75 percent
Published on 10/01/2026 at 08:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AstraZeneca stock was at EUR 142.18 pre-market at 8:45 a.m. CEST on October 1, 2026, down 0.75 percent versus the EUR 143.25 prior close at Lang & Schwarz on September 30, 2026.
Pre-market price
Lang & Schwarz showed a bid of EUR 141.80 and an ask of EUR 142.55. The further course from the Xetra open at 9:00 a.m. CET/CEST is shown by the continuously updated real-time quote of AstraZeneca stock.
Earlier company development
In a September 8, 2026 release, AstraZeneca reported positive high-level results from an interim analysis of the DeLLphi-305 Phase III trial. The company said Imfinzi plus Amgen’s tarlatamab produced a statistically significant and clinically meaningful improvement in overall survival versus Imfinzi alone as first-line maintenance treatment for patients with extensive-stage small-cell lung cancer.
The release said progression-free survival and objective response rate also improved significantly. The trial randomized 563 patients who had completed Imfinzi-based induction treatment, and the data were to be presented at a forthcoming medical meeting and shared with global regulatory authorities.
